The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS).
 
Sandra P. D'Angelo
Honoraria - Adaptimmune; GlaxoSmithKline; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Nektar; Pfizer; Rain Therapeutics; Rain Therapeutics; Servier
 
Mihaela Druta
Consulting or Advisory Role - Adaptimmune; Deciphera; Epizyme
Speakers' Bureau - Deciphera
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
David A. Liebner
Consulting or Advisory Role - Blueprint Medicines; Epizyme; Foundation Medicine
Patents, Royalties, Other Intellectual Property - Co-holder of 2 patents ("Methods for Predicting Prognosis") that has been licensed to a private company, MatchTX, LLC.
Travel, Accommodations, Expenses - Blueprint Medicines; Epizyme; Foundation Medicine
 
Scott Schuetze
Consulting or Advisory Role - Adaptimmune; Boehringer Ingelheim
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst)
 
Michael Nathenson
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - Bristol-Myers Squibb; Johnson & Johnson; Merck
Expert Testimony - US DOJ; US DOJ
 
Andrew P. Holmes
Employment - Phastar (I); Veramed
Travel, Accommodations, Expenses - Veramed
 
Jimson D'Souza
Employment - GlaxoSmithKline
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Gurpreet Singh Kapoor
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Stefan Zajic
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Ascentage Pharma; AstraZeneca/MedImmune (Inst); Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics